Illumina, Inc.
NASDAQ:ILMNMedical - Diagnostics & Research
+$1.95 today
- Market cap
- $31.75B
- Beta
- 1.49
- P/E (TTM)
- 28.9
- EPS (TTM)
- $5.58
Volume 1.63M
Average 1.65M
ILMN Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Illumina, Inc.NASDAQ: ILMN
Net Income · Q2 FY2026 · quarter ended Jun 2026
Net income growth accelerates
Q2 FY2026 net income of $134M (cash outflow) rose 2.3% year over year, ahead of the -45.7% change in trailing-twelve-month net income.
Context
- Net income amounted to 19.6% of revenue in FY2025, down 8.4 pp from a year earlier.
- Net income increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 14 analysts of $838.72M (-1.3%) for the fiscal year ending Dec 2026, a slowdown from the +169.5% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- -$134M-200.0% QoQ
- Last fiscal yearDec 2025
- $850M+169.5% YoY
- LTMJun 2026
- $484M-45.7% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +2.3% | +39.3% | +37.0 pp |
| 1 year | +169.5% | -1.3% | -170.8 pp |
| 3-year CAGR | — | +8.9% | — |
| 5-year CAGR | +10.4% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- 850M USD
- Year-over-year change
- +169.5%
- 4-year CAGR
- +2.8%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-28 | 850M | +169.5% |
| FY2024 | 2024-12-29 | (1.22B) | -5.3% |
| FY2023 | 2023-12-31 | (1.16B) | +73.6% |
| FY2022 | 2023-01-01 | (4.4B) | -678.0% |
| FY2021 | 2022-01-02 | 762M | — |
Net Income vs competitors
How ILMN compares with its peers on the latest reported figures
- ILMN's LTM Jun 2026 net income of $484M is the 2nd largest of the 11 companies compared; the peer median is $100.95M.
- Its year-over-year change of -45.7% is the 7th highest of 10, against a peer median of -11.2%.
- Net income amounts to 10.8% of revenue for ILMN, versus a peer median of 30.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $485.07M | +21.6% | -14.0% | 37.9% | |
| LTM Jun 2026 | $484M | -45.7% | — | 10.8% | |
| LTM Mar 2026 | $399.9M | +294.4% | +48.4% | 48.2% | |
| LTM Jun 2026 | $192.35M | -24.0% | -27.6% | 7.1% | |
| LTM Mar 2026 | $128.58M | -80.5% | +20.2% | 80.3% | |
WGSGeneDx Holdings Corp. | LTM Jun 2026 | $106.36M | -7664.5% | -66.3% | 23.4% |
| LTM Mar 2026 | $95.55M | +13.7% | -10.5% | 148.1% | |
| LTM Mar 2026 | $80.17M | +23.8% | -3.4% | 98.8% | |
| LTM Jun 2026 | $75.13M | -11.2% | -36.0% | 12.2% | |
| LTM Jun 2026 | $51.88M | -50.1% | -9.2% | 6.8% | |
BLLNBillionToOne, Inc. | LTM Jun 2026 | $37.71M | — | — | 9.5% |
| Peer median (excluding ILMN) | $100.95M | -11.2% | -10.5% | 30.7% | |
Competitors are the stored peer set for ILMN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Jan 2022 | FY2022 Jan 2023 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 762M | (4.4B) | (1.16B) | (1.22B) | 850M |
| Depreciation & Amortization | 251M | 394M | 432M | 354M | 270M |
| Deferred Income Tax | (76M) | (23M) | (33M) | (112M) | 119M |
| Stock-Based Compensation | 754M | 366M | 380M | 370M | 275M |
| Change in Working Capital | (152M) | 204M | (90M) | (483M) | (153M) |
| Accounts Receivables | (164M) | (12M) | (40M) | (25M) | (108M) |
| Inventory | (58M) | (135M) | (20M) | 19M | (17M) |
| Accounts Payables | 60M | (38M) | (44M) | (4M) | 2M |
| Other Working Capital | 10M | 389M | 14M | (473M) | (30M) |
| Other Non-Cash Items | (994M) | 3.86B | 950M | 1.93B | (282M) |
| Operating Cash Flow | 545M | 392M | 478M | 837M | 1.08B |
| Capital Expenditures | (208M) | (286M) | (195M) | (128M) | (148M) |
| Acquisitions (Net) | (2.44B) | (265M) | (29M) | 2M | (10M) |
| Purchases of Investments | (77M) | (40M) | (6M) | (52M) | 0 |
| Sales of Investments | 1.66B | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | (1M) | 0 | 103M |
| Investing Cash Flow | (1.07B) | (591M) | (231M) | (178M) | (55M) |
| Debt Repayment | 471M | 991M | (1.24B) | 491M | (5M) |
| Common Stock Issued | 60M | 63M | 67M | 56M | 44M |
| Common Stock Repurchased | 0 | 0 | 0 | (116M) | (742M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (582M) | (54M) | (42M) | (1B) | (41M) |
| Financing Cash Flow | (51M) | 1B | (1.21B) | (570M) | (744M) |
| Effect of Forex Changes | (3M) | (22M) | 0 | (10M) | 11M |
| Net Change in Cash | (578M) | 779M | (963M) | 79M | 291M |
| Free Cash Flow | 337M | 106M | 282M | 709M | 931M |
Illumina, Inc.
NASDAQ:ILMN
Intrinsic Alpha fair value
Locked
Current Price
$210.01
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.